Full Text View
Tabular View
No Study Results Posted
Related Studies
Matrix Metalloproteinases and Diabetic Nephropathy
This study is ongoing, but not recruiting participants.
Study NCT00067886   Information provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First Received: August 29, 2003   Last Updated: March 4, 2009   History of Changes

August 29, 2003
March 4, 2009
March 2003
 
 
 
Complete list of historical versions of study NCT00067886 on ClinicalTrials.gov Archive Site
 
 
 
Matrix Metalloproteinases and Diabetic Nephropathy
Matrix Metalloproteinases and Diabetic Nephropathy

Matrix metalloproteinases (MMPs) are a family of protein-degrading enzymes that are involved in the breakdown and remodeling of many tissues and organs. Abnormal activity of these enzymes has been implicated in many disease processes including rheumatoid arthritis, dental disease and metastatic cancer. Recent studies also suggest that elevations in blood sugar may abnormally effect MMP enzyme activity. Decreased activity of some of these MMP enzymes may be a partial cause of the abnormal enlargement of the kidney (renal hypertrophy) seen at the start of diabetic kidney disease (nephropathy). Preliminary clinical data from our laboratory confirm that children with newly diagnosed type 1 diabetes mellitus (DM) have lower blood levels of some of these enzymes at the time of very high blood sugar readings. However, these enzyme levels become normal again as blood sugar levels improve with insulin treatment. In the present study, we propose to investigate the hypothesis that MMPs are involved in the cause of diabetic kidney disease by measuring concentrations of specific MMPs and some related proteins in the blood and urine of patients with type 1 DM who are between the ages of 14-40 years. We will enroll some patients who are recently diagnosed with diabetes, some who have had diabetes for several years, but without signs of kidney disease, and some with long-term diabetes and various degrees of kidney disease. Continuous Subcutaneous Glucose Monitoring, conducted for 3-4 days, will also be provided as a part of this study, to determine how different levels of blood sugar control might relate to different levels of MMP enzyme activity in the blood. We anticipate that this study will help to establish a link between abnormal MMP activity and the cause of nephropathy in type 1 DM, allowing scientists to design better therapies for the prevention and treatment of diabetes-related kidney problems.

 
 
Observational
Case Control, Cross-Sectional
  • Diabetes Mellitus, Type 1
  • Diabetic Nephropathy
 
 
Thrailkill KM, Bunn RC, Moreau CS, Cockrell GE, Simpson PM, Coleman HN, Frindik JP, Kemp SF, Fowlkes JL. Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care. 2007 Sep;30(9):2321-6. Epub 2007 Jun 11.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
330
December 2008
 

Type 1 Diabetes with or without kidney disease and past puberty.

Both
14 Years to 40 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00067886
Kathryn Thrailkill, Arkansas Children's Hospital Research Institute
MMADN (DK62999)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
 
Principal Investigator: Kathryn M Thrailkill, MD Arkansas Chilldren's Hospital Research Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP